---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-017915"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2025-02-11T23:59:59+00:00"
generated_at: "2026-05-26T23:19:51.108066+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adaptive Biotech Q4 revenue $47.5M; MRD revenue up 31% YoY; FY2025 MRD guidance $175-185M

## Summary
- Q4 total revenue $47.5M (+4% YoY); full year $179.0M (+5%). MRD revenue $40.1M (+31% Q4, +42% FY).
- clonoSEQ test volume Q4 20,945 tests (+34% YoY); full year 76,105 tests (+35%).
- Net loss Q4 $33.7M vs $69.5M a year ago; FY net loss $159.6M vs $225.3M. Adjusted EBITDA loss Q4 $16.4M vs $24.7M.
- FY2025 guidance: MRD revenue $175-185M; total operating expenses $340-350M; cash burn $60-70M.
- FDA ODAC unanimously voted to support MRD as primary endpoint for accelerated approval in multiple myeloma.

## SEC filing metadata
- accession: 0000950170-25-017915
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2025-02-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000095017025017915/0000950170-25-017915-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000095017025017915/adpt-20250211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-017915
- JSON: https://secwatch.observer/filing/0000950170-25-017915.json
- Plain text: https://secwatch.observer/filing/0000950170-25-017915.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.